Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Ivan SpickaPhillipe MoreauThomas G MartinThierry FaconGracia MartinezAlbert OrtiolYoungil KohAndrew LimGabor MikalaLaura RosiñolMünci YağciMichele CavoMarie-Laure RisseGaëlle AssetSandrine MacéHelgi van de VeldeKwee Yong

Published in: European journal of haematology (2022)

Isa-Kd is a new treatment option for the difficult-to-treat subgroup of patients with relapsed MM and high-risk cytogenetics.

Keyphrases

multiple myeloma
acute lymphoblastic leukemia
acute myeloid leukemia
low dose
phase iii
high dose
diffuse large b cell lymphoma
hodgkin lymphoma
clinical trial
randomized controlled trial
combination therapy
smoking cessation